PMID- 33176589
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - Comprehensive Comparison of Progressive Optimization Algorithm Based Automatic 
      Plan and Manually Planned Treatment Technique for Cervical-Thoracic Esophageal 
      Cancers.
PG  - 1533033820973283
LID - 10.1177/1533033820973283 [doi]
LID - 1533033820973283
AB  - PURPOSE: The purpose of the present study was first to apply the progressive 
      optimization algorithm based automatic volumetric modulated arc therapy 
      (POA-VMAT) technology to accelerate and improve the radiotherapy of 
      cervicothoracic esophageal cancer (CTEC). We comprehensive analyze the 
      feasibility, normal tissue complication probability (NTCP) and dosimetric results 
      of POA-VMAT, manual based VMAT and step-shoot intensity-modulated radiation 
      therapy (IMRT) plans in the treatment of CTEC. METHODS: Sixty patients with CTEC 
      with or without concomitant chemotherapy at our institution between 2017 and 2019 
      were retrospectively identified. The manual 7field-IMRT (7f-IMRT), 
      Single-arc-VMAT and Double-arc-VMAT (Single-Arc/Double-Arc) plans were generated 
      in all cases. The POA-VMAT was designed using the automatic dual-arc VMAT 
      technology of Pinnacle(3) 9.10 planning system based on progressive optimization 
      algorithm. Specially, it includes the selection of treatment techniques, the 
      running of automated planning scripts, and the evaluation of the final 
      radiotherapy regimen. Subsequently, quantitative evaluation of plans was 
      performed by means of standard dose-volume histograms, homogeneity index (HI) and 
      conformity index (CI). RESULTS: Target dose conformity of the 7f-IMRT plan was 
      inferior to all plans, whereas the Double-Arc plan was slightly inferior to the 
      POA-VMAT but superior to the Single-Arc and 7f-IMRT plan. The HI for 7f-IMRT, 
      Single-Arc, Double-Arc and POA-VMAT were 0.17 +/- 0.08, 0.28 +/- 0.06, 0.29 +/- 0.06 
      and 0.28 +/- 0.03, respectively. For the NTCP results, there was significant 
      statistical difference among POA-VMAT, IMRT and VMAT plans. The total MU was 
      reduced by 48.3% and 42.1% in Single-Arc and POA-VMAT plans compare to IMRT 
      plans. CONCLUSIONS: By comprehensive consideration, POA-VMAT efficiently generate 
      acceptable treatment plans for CTEC without dose escalation to OARs and overall 
      superior to manual planning which is a good option for treating CTEC.
FAU - Zhou, Yongqiang
AU  - Zhou Y
AD  - Department of Radiation and Medical Oncology, 89657Wenzhou Medical University 1st 
      Affiliated Hospital, Wenzhou, China.
FAU - Xiang, Xiaojun
AU  - Xiang X
AD  - Department of Oncology, 117970The First Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Xiong, Jianping
AU  - Xiong J
AD  - Department of Oncology, 117970The First Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Gong, Changfei
AU  - Gong C
AUID- ORCID: 0000-0002-1935-9684
AD  - Department of Oncology, 117970The First Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
SB  - IM
MH  - Algorithms
MH  - Clinical Decision-Making
MH  - Disease Management
MH  - Esophageal Neoplasms/diagnosis/*radiotherapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Multimodal Imaging/methods
MH  - Organs at Risk
MH  - Radiometry
MH  - Radiotherapy Dosage
MH  - *Radiotherapy Planning, Computer-Assisted/methods
MH  - Radiotherapy, Image-Guided/methods
MH  - Radiotherapy, Intensity-Modulated/*methods
PMC - PMC7672719
OTO - NOTNLM
OT  - automatic
OT  - cervical-thoracic esophageal cancers
OT  - intensity-modulated radiotherapy
OT  - normal tissue complication probability
OT  - volumetric-modulated arc therapy
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/11/13 06:00
MHDA- 2021/11/26 06:00
PMCR- 2020/11/11
CRDT- 2020/11/12 05:29
PHST- 2020/11/12 05:29 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/11/11 00:00 [pmc-release]
AID - 10.1177_1533033820973283 [pii]
AID - 10.1177/1533033820973283 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820973283. doi: 
      10.1177/1533033820973283.